■ Defi nitions
The history of endocarditis dates as far back 1723 where Lazaire Riviere fi rst described gross autopsy fi ndings of the disease. 1 Then it was the Gulstonian lectures of 1885 where Sir William Osler (hence "Osler nodes") drew a distinction between "simple" and "malignant" forms of the disease. The "simple" form of endocarditis correlates to what now has become SBE and the "malignant" form is now characterized as an acute onset and fulminant course referred to as acute infective endocarditis (IE) or acute bacterial endocarditis (ABE). 2 It is worthy to note that many studies of diagnosis and treatment of endocarditis do not differentiate between acute and subacute disease process, and many principles of diagnosis and management are identical. 3 Some physician researchers also argue that the distinction between subacute and acute is not useful for clinical management and is arbitrary. The opinion is that the focus of diagnosis and clinical relevance should be on the causative organism involved (such as Staphylococcus aureus bacterial endocarditis). 4, 5 Some types of endocarditis are also not caused by bacteria (that is, Haemophilus parainfl uenzae, fungi, culture negative), so using the word "bacteria" in diagnosis may be misleading.
In the literature, clear-cut definitions of SBE versus ABE have been published by Burke A. Cunha, MD, Chief, Infectious Disease Division, Winthrop-University Hospital, Mineola, N.Y. [6] [7] [8] In Dr. Cunha's work, he characterizes SBE by fever less than 102º F, a heart murmur, a continuous bacteremia with possible aseptic emboli phenomenon, primarily caused by viridian streptococci from the oral cavity, an avirulent organism causing endocarditis in patients with preexisting valvular heart disease, and a variety of peripheral manifestations. The majority of organisms responsible for SBE are avirulent/noninvasive pathogens of viridans streptococci, which include S. sanguis, S. intermedius, S. sanguinis, S. anginosus, S. salivarius, S. mutans, and others. [6] [7] [8] SBE may pursue a protracted course of weeks to months, cures may be produced with antibiotics alone, and a later mortality ensues (up to a year) if not treated. 9 ABE is characterized by more dramatic symptoms such as a continuous bacteremia, temperatures spiking over 102º F, frequent septic embolic complications (metastatic focus), an acute and virulent organism attacking both damaged and normal heart valves (more often normal), and a new murmur with valvular destruction. 6, 8 Due to the dangers of septic embolic phenomena, myocardial abscesses, valve destruction, sepsis, and diffi culty curing with antibiotics, ABE is usually treated as a medical emergency requiring cardiac valvular replacement. If untreated, an earlier mortality ensues. 8, 9 (See Clinical differences between SBE and ABE). Nosocomial endocarditis (NE) is considered a hospitalacquired form of ABE. It has similar characteristics in that it is acute, temperatures over 102º F, and affects normal heart valves. NE is usually related to an intracardiac device placed in the hospital setting such as temporary central venous catheters, pulmonary artery catheters, and pacemakers. The importance of the skin prep for the introduction of percutaneous central devices cannot be emphasized enough because MSSA (methicillin-sensitive S. aureus) and MRSA (methicillin-resistant S. aureus) are the usual pathogens of cause. 6 Sherwood et al. compared outcomes of MSSA endocarditis with MRSA endocarditis and found no signifi cant difference. 10 Similarly, there is prosthetic valve endocarditis (PVE), which involves an infection of a prosthetic cardiac valve or relating structure. In this situation patients would have bacteremia and cardiac vegetation on the prosthetic structure. PVE is frequently caused by coagulase-negative staphylococci (CoNS), which is a normal skin fl ora. 8, 11 The importance of skin prep must be emphasized, along with the practitioner's ability to recognize the possibility of endocarditis in prosthetic valve patients with positive blood cultures of CoNS. CoNS may not just be a skin contaminant in these patients.
Nonbacterial thrombotic endocarditis (NBTE) is characterized with small sterile thrombi on the leafl ets of the cardiac valves that do not elicit any infl ammatory reaction but can become systemic emboli producing infarcts. NBTE is usually seen in debilitated patients in a hypercoagulable state, such as cancer or sepsis, and has been referred to as marantic endocarditis in the past. Finally there is Libman-Sacks endocarditis, which is occasionally encountered in systemic lupus erythematosus (SLE). These vegetations are sterile and may be encountered with a valvulitis in this disorder. per 1,000 admissions. 4 The American Heart Association (AHA) places the annual incidence of IE in the United States at 10,000 to 20,000 new cases. 12 Although the primary causes of endocarditis have varied, the incidence of the disease has remained relatively the same over the past 30 years. However, this epidemiology may possibly vary due to changes in the diagnostic criteria of endocarditis and changes in defi nitions over time. 4 Endocarditis is more common in men and the incidence increases with age due to the current, low incidence of acute rheumatic heart disease. 13, 14 It is also more commonly involved with the mitral valve only (40%), followed by the aortic valve only (36%), and followed by multivalvular disease. [15] [16] [17] Rheumatic heart disease was the most common cause of endocarditis in the preantibiotic era. Nowadays about 75% of patients who develop endocarditis have some type of underlying structural heart disease (that is, congenital or calcifi cation). These include mitral regurgitation; aortic valve disease, including stenosis and regurgitation; and congenital heart disease. [17] [18] [19] Prosthetic valves (1% to 4% 1st year), prior history of endocarditis, invasive medical procedures, drug use, healthcare-associated infections, societal hazards as in body piercings, and some systemic medical conditions (that is, HIV, end-stage kidney disease, diabetes mellitus) are also among risk factors. 4, 17 The majority of the time a rightsided heart valve involvement is a good indication of I.V. drug abuse (tricuspid valve-78% of cases, mitral-24%, and aortic-8%). 4 S. aureus has been identifi ed as the most common pathogen worldwide in endocarditis, 20, 21 and embolic risk has been found to be the highest among the fi rst days following the initiation of antibiotics and in cases where the vegetation is very large and mobile ( greater than 15 mm). 22 
■ Pathophysiology
Endocarditis is the infl ammation of the part of the heart that lines the cardiac chambers called the endothelial layer and the endocardium, which is the origin of the large vessels in direct proximity to the heart. This inflammation can be attributable to infectious or noninfectious causes and mainly refers to the inflammation of the heart valves themselves. The heart valves consist 
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of three normal membranous layers called the fi brosa, the spongiosa, and the laminosa, which are all covered on both sides by endothelial cells. There are also different types of these endothelial cells called microvascular endothelial cells, arteriolar endothelial cells, aortic endothelial cells, and venous endothelial cells. The function of these endothelial cells includes regulating vascular tone, permeability, coagulation, fi brinolysis, and an infl ammatory response to defend against an invading microorganism. When these cells are invaded by an organism, endothelial cell injury and dysfunction results with alterations in vascular permeability, leukocyte and platelet activation and adhesion, and homeostasis. The entire infl ammatory cytokine cascade begins similar to sepsis. 23 Specifi cally to SBE, Presterl et al. found the decreased response of patient monocytes to the pathogens may contribute to the low-grade infl ammatory response and to the course of streptococcal endocarditis. 24 The destructive nature of endocarditis is a result of pathogens exerting a brisk infl ammatory response. Monocyte attraction, ulceration, tissue destruction, and fi brotic scarring eventually affect valve function and myocardial hemodynamics. In addition to this immune response, the type of pathogen itself largely impacts the course and severity of endocarditis. 23 Many researchers view the hallmark of endocarditis as the presence of friable, bulky, potentially destructive vegetations containing fi brin, infl ammatory cells, and bacteria or other organisms on the heart valves. 9 Vegetations develop due to the previously mentioned infl ammatory activation of the endothelium, which disrupts the endothelial cell barrier in many ways. When viewed under a microscope, white blood cells that the body uses to fi ght infection are uncommon. This fi nding explains why antibiotics are needed for many weeks to kill the infecting organism (see Bacterial endocarditis). Although not completely understood, the absence of white blood cells may likely relate to the dense nature of the vegetation tissue where the bacteria causing endocarditis is buried in a nongrowing state deep in the vegetation. 25 Specifi cally the vegetations of SBE are associated with less valvular destruction and have granulation tissue indicative of healing at their bases. There lie many dangers in regard to the vegetation. They can erode into the underlying myocardium and produce a ring abscess. Or, they can embolize causing infection at the sites where the emboli lodge, stroke, or a variety of other dangerous organ infarctions. 9, 23 Even in these modern times of medicine, there is still very little known about the specifi c role of the endothelium in the pathogenesis of endocarditis and induction of endocardial infl ammation. Studies continue to analyze the ability of bacteria to attach to the endothelial cells by means of cell-envelope glycopolymer found on certain specifi c bacteria such as teichoic acid, lipoteichoic acid, and fi bronectin. 23 Banks et al. identifi ed two bacterial proteins (involving S. Sanguis endocarditis) as being responsible for the majority of the cytokine induction. They hypothesized that these proteins, or the receptors to which they bind, may be therapeutic targets and may allow the development of adjunctive therapies to prevent endocardial damage during the treatment of endocarditis. 26 
■ Presentation History
The presentation of endocarditis varies from patient to patient, making it diffi cult sometimes to diagnose correctly as in the previous case study. While some patients will develop symptoms acutely over days, others' symptoms develop over weeks or months as in SBE. Most patients complain of fever and nonspecifi c constitutional symptoms, such as fatigue, malaise, and weight loss, along with 50% complaining of frank arthritis to diffuse myalgias. 27 It is important to note that patients who report muscular skeletal symptoms that have been misdiagnosed as rheumatic disorders may be inappropriately treated with steroids. 8 These patients may actually have SBE. With the use of corticosteroids for nonspecifi c symptoms, SBE can be easily masked and therefore the diagnosis of endocarditis can be delayed. Other chief complaints may include dyspnea, headache, backache, chills, chest pain, and anorexia. 1 The presentation of ABE varies from SBE in that they are resulting from either embolic or intracardiac suppurative complications. ABE's onset is abrupt, and causes rapid progressive destruction of the infected valve. The infected valve is destroyed by the bacteria that rapidly multiply within the friable vegetations. The complications that develop include severe dyspnea and fatigue resulting from 1 In the review of symptoms, questions should include any history of abrupt onset or a protracted course of fl ulike symptoms. Because it is well known that bacteremia can result from various invasive procedures, the patients should be questioned on any history of periodontal disease and/or dental work, preexisting heart anomalies, or history of gastroinstinal and urinary tract procedures. The potential for invasive procedures to produce a bacteremia varies greatly; however, healthcareassociated bacteremias (mostly associated with intravascular lines) have more than doubled in the last few years. 
■ Physical exam
Due to the sometimes vague symptoms of SBE, an extremely thorough physical exam needs to be performed. Fever is present in nearly 50% of patients in most studies; however, elderly patients and patients with renal failure or heart failure may be less likely to have a febrile response. 27 Embolic phenomena may be present, such as petechiae, splinter hemorrhages, and Osler nodes, all of which are seen on the skin of the hands and feet, as well as the conjunctiva and palate. 5 Osler nodes have been traditionally reported as painful red-purple raised cutaneous nodules in association with SBE, which may exemplify more pathogenesis of an immunologic phenomenon. Although some crossover is hypothesized among the two types of skin lesions, the painless Janeway lesions are believed to be more associated with ABE, and be more a product of the septic microemboli. 28 Eighty-fi ve percent of patients have a new, audible murmur, either systolic or diastolic, and any evidence of heart failure is a late sign. Splenomegaly is also a fi nding that is commonly present on physical exam in SBE. Finally, a neurologic exam should be included for any signs of major vessel embolism, visual fi eld defects, or altered mental status, and also to serve as a baseline for any changes in the future. Purulent meningitis may be observed in patients with ABE compared with the aseptic type observed in SBE. 1 
■ Diagnosis
The diagnosis of SBE is usually through the gold standard of positive blood cultures, along with presenting clinical symptoms. In the diagnosis of this disease, the most widely accepted clinical criteria is the Duke criteria, which have an estimated 76% to 100% sensitivity, and 88% to 100% specifi city, with a negative predictive value of at least 92%. 27 This criterion relies on blood culture and echocardiogram data to make a defi nitive diagnosis.
(See Modifi ed Duke criteria for the diagnosis of IE).

Lab tests
The criterion standard test for diagnosing SBE is the documentation of a continuous bacteremia based on blood culture results. The growth of Gram-positive bacteria is the most common pathogens causing endocarditis. Staphylococcal endocarditis is the most severe form of the disease, occurring in 3 to 4 cases per 10,000 hospital admissions, and in 10% to 25% of endocarditis cases. 29 Streptococcus viridans is also one of the more common organisms causing SBE, and most commonly occurs in the setting of preexisting valvular disease. Exceptions to positive blood cultures are observed on patients with PVE and right-sided IE.
1 False-negative culture results are also seen with prior use of antibiotics. In diagnosing SBE, three to fi ve sets of blood cultures are needed for confi rmation of diagnosis. Other lab work should include complete blood cell count with differential to evaluate anemia, possible leukocytosis with a left-sided shift, along with elevated erythrocyte sedimentation rate (ESR), RF titer, and Venereal Disease Research Laboratories (VDRL) titers. Hematuria may also be present in urinalysis.
CXR
A chest X-ray with an anterior/posterior and lateral view may be abnormal, with consolidation, atelectasis, pleural effusions, or evidence of HF. Septic pulmonary emboli may be present in ABE.
Imaging studies
Primarily performed in the diagnostic workup of SBE, a 2-D transthoracic echocardiogram (TTE) can detect 85% of vegetations. 1 Transesophageal echocardiograms (TEE) are indicated when the patient has a mechanical prosthetic valve or to visualize any myocardial abscesses. Immunoscintigraphy with Tc-Fab-1 fragments in combination with TEE improves diagnostic accuracy with TTE/TEE in patients with SBE. 30 ECGs are done to detect whether there is any conduction delays that may be present. Multislice computed tomography (CT) scans of the chest for valvular images and also of the head (for those who show CNS symptoms) are also helpful in the diagnostic workup.
Embolic phenomena may be present, such as petechiae, splinter hemorrhages, and Osler nodes.
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■ Complications
The mortality in non-I.V. drug users with acute/subacute endocarditis with S. aureus is approximately 40%. 31 Valve replacement may be required, especially when the aortic valve is involved in ABE. 32 Complications occur when vegetations embolize to blood vessels and organs causing mycotic aneurysms, infarcts, abscesses, and arteritis. 33 Cerebral arteries and the spleen are the most frequent sites of embolization in left-sided SBE, whereas pulmonary embolism is frequent in right-sided and pacemaker lead SBE. 22 These embolic events are a frequent and sometimes life-threatening complication of SBE, and are associated with higher mortality and morbidity. Sepsis and multisystem organ failure may also result in severe cases of ABE that have either gone too far without ample treatment (late diagnosis) or are not responding to present treatment.
■ Treatment
The primary goals of therapy for IE are to eliminate the infectious agent and address the complications, if any, of the valvular infection. In heart failure, which results from insuffi ciency of the valve affected, medical management is the treatment of choice. If the disease is progressive, despite achieving a cure with antibiotic therapy, valve surgery is the end choice of treatment.
Traditionally, antibiotic therapy has been the standard of care and the main choice of treatment for SBE. In SBE, treatment may be safely delayed until results of the cultures and sensitivities are available, if the patient is clinically stable without evidence of HF or end-organ complications. I.V. administration of antibiotics for 4 to 6 weeks has been the preferred, traditional route because of the more reliable therapeutic levels that are achieved. Definitive treatment with antibiotics is guided by the responsible pathogen that has been isolated from the culture specimens. When the correct organism or pathogen has been clearly identifi ed, the culture sensitive treatment regimen can begin. The standard therapy for endocarditis that is caused by enterococci includes penicillin or ampicillin plus gentamicin. When the endocarditis is caused by S. aureus, the choice of antibiotics is nafcillin plus gentamicin or vancomycin or daptomycin plus gentamicin. Another alternative is cefazolin plus gentamicin. These types of combination therapies are the most appropriate empirical coverage for patients with native valve endocarditis (NVE). If MRSA is suspected and/or confi rmed, the drugs of choice are vancomycin and gentamicin, as well as with patients who are penicillin allergic. In those cases where patients have a PVE, the treatment of choice is vancomycin, gentamicin, and rifampin. Patients should have blood cultures taken after 3 to 4 days of treatment to document the eradication of the bacteremia and are especially important if persistent fever or other signs develop that suggest failing treatment. Failure to eradicate the bacteremia or fever lasting longer than 10 days should prompt a search for superlative complications (for example, abscesses or metastatic infections). 1 Patients with IE/SBE may eventually require surgery. In patients who have a NVE, the primary indicator for surgery is heart failure. This is especially indicated when during antibiotic therapy, or after completion of antibiotics, there is a second relapse of symptoms. Patients with paravalvular abscess or persistent hypermobile vegetations should be treated with surgery, 1 especially in those with history of embolization and fevers after 7 days of antibiotic therapy. Mitral valve repair using Carpentier techniques in patients with active endocarditis offers very good long-term results with a low rate of recurrence or reoperation. 34 Early surgery for NVE is associated with an in-hospital mortality benefi t compared with medical therapy alone. 35 If early surgical intervention is necessary then antibiotic therapy is still required for 4 to 8 weeks after the procedure.
Finally, in an attempt to decrease length of stay and prolonged parenteral therapy, I.V.-to-oral switch programs have been used successfully to treat ABE/SBE caused by a variety of organisms. 36 Most patients in need of long-term I.V. antibiotics require a peripherally inserted central catheter line that necessitates additional patient education and monitoring.
■ Prognosis
When IE/SBE is left untreated, the end result is usually fatal. However, with aggressive medical and possibly surgical treatment, the outcomes for patients are dramatically different. For the appropriately managed NVE patient the cure rates are as follows: S. viridans and S. bovis infection-98%, enterococci and S. aureus infection who abuse I.V. drugs-90%, community-acquired S. aureus infection in individuals who do not abuse I.V. drugs-60% to 70%, infection with aerobic Gram-negative organisms-40% to 60%, and infections with fungal organisms-less than 50%. For appropriately managed PVE, the cure rates are 10% to 15% lower for all previously mentioned organisms in NVE, surgery is required more frequently, and approximately 60% of early CoNS PVE cases and 70% of late CoNS PVE cases are curable. 1 
■ Prevention
In 1997, the AHA guidelines recommended prophylactic antibiotics for the prevention of SBE for cardiac conditions with a high to moderate risk of SBE. These conditions include prosthetic heart valves, history of bacterial endocarditis, complex cyanotic congenial heart disease, congenital malformations, acquired valvular heart disease, mitral valve prolapsed with regurgitation, and hypertrophic cardiomyopathy. These cardiac conditions all required prophylactic antibiotics depending on type of procedure being performed. 12, 37 In April 2007, the AHA revised the guidelines about the role of antimicrobials in the prevention of IE. 12 These new guidelines were based on in vitro studies, clinical experience, and experimental animal model, rather than randomized controlled clinical trials. They recommended a more narrowed range in cardiac conditions and medical/dental procedures when antibiotic prophylaxis is indicated. The AHA concluded that antibiotic prophylaxis may prevent only a small number of SBE cases for those patients who undergo invasive procedures and also that there is a greater risk in the adverse reactions of the antibiotic rather than the proven benefi t from prophylaxis. The recommendation is to use antibiotic prophylaxis for those individuals only at high risk for SBE. These include individuals with prosthetic heart valves, a history of infectious endocarditis, an unrepaired congenital heart disease, a repaired congenital heart defect with prosthetic material or a device, any repaired congenital heart defect with residual defects near the prosthetic device, or cardiac valvulopathy in a transplanted heart. 12, 38 The AHA also created a wallet card that specifi cally details the dosage/antibiotics for those patients at risk for endocarditis.
■ Conclusions
Future considerations for the treatment of endocarditis include improvements in cardiac imaging technology for the diagnosis of the presence of vegetation. Agents that prevent the formation or promote the dissolution of the vegetation are also being examined, along with the ongoing improvement in antibiotics. This improvement includes the investigation of involving cell wall-specifi c enzymes and antibacterial antibodies that act as adjuncts to antibiotics in facilitating bacteriologic clearance. 4 SBE can have serious consequences, and the potential for malpractice litigation due to failure to diagnose or
Future considerations for the treatment of endocarditis include improvements in cardiac imaging technology.
Subacute bacterial endocarditis: making the diagnosis delayed diagnosis accompanied by a poor outcome for the patient. There have been documented case studies of failure of the current AHA recommendations even when they are applied appropriately. 7 Therefore, NPs must follow the revised 2007 AHA guidelines, keeping in mind that they may need modifi cation in particular circumstances based on the individual clinical setting and risk of developing SBE. Overall, the key to maximizing treatment success is knowledge of this disease process and early diagnosis. SBE is complex, and the clinical team must have an understanding of the epidemiology, microbiology, and natural history of endocarditis, as well as a grasp of the AHA guiding principles of prophylaxis, diagnosis, and medical and surgical management.
